ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - bolezen tipa ii za shranjevanje glikogena - drugi zdravljene bolezni prebavil in presnove izdelki, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - bolezen tipa ii za shranjevanje glikogena - drugi zdravljene bolezni prebavil in presnove izdelki, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabryjeva bolezen - drugi zdravljene bolezni prebavil in presnove izdelki, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

amicus therapeutics europe limited - miglustat - bolezen tipa ii za shranjevanje glikogena - drugi proizvodi prebavnega trakta in metabolizma - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - neoplazme dojke - endokrini terapije, anti-estrogene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. v pre - ali perimenopausal ženske, kombinacija zdravljenja z palbociclib je treba v kombinaciji z luteinizirajoči hormon sproščujoči hormon (lhrh) agonist.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

pfizer europe ma eeig - palonosetronijev hidroklorid - nausea; vomiting; cancer - antiemetics in antinauseants, - palonosetron hospira je navedeno v odraslih za:preprečevanje akutne slabosti in bruhanja, povezanih z močno emetogenic raka kemoterapijo;preprečevanje slabosti in bruhanja, povezanih z zmerno emetogenic kemoterapijo raka. palonosetron hospira je navedeno v pediatričnih bolnikih od 1 meseca starosti in starejših za:preprečevanje akutne slabosti in bruhanja, povezanih z močno emetogenic rak, kemoterapija in preprečevanje slabosti in bruhanja, povezanih z zmerno emetogenic kemoterapijo raka.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karcinom, pljučni pljuč - antineoplastična sredstva - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - alprostadil - prašek in vehikel za raztopino za injiciranje - alprostadil 23,5 µg / 1 viala - alprostadil

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - alprostadil - prašek in vehikel za raztopino za injiciranje - alprostadil 11,9 µg / 1 viala - alprostadil

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

servier pharma d.o.o. - bisoprolol; perindopril - filmsko obložena tableta - bisoprolol 8,49 mg / 1 tableta  perindopril3,395 mg / 1 tableta; perindopril 3,395 mg / 1 tableta - bisoprolol in perindopril